Accuracy Coverage Pricing Contact
Galapagos NV

Galapagos (GLPG)

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives.

Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using our proprietary target discovery technology, and is being developed by Gielad in Phase 3 in rheumatoid arthritis, Crohn's disease and ulcerative colitis. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.

Galapagos is listed on Euronext Amsterdam and Brussels and on the NASDAQ; all with the ticker symbol GLPG.


Optimized Dividends

Annual Dividends

Year Amount Change
2006 0.0¢
2007 0.0¢ 0%
2008 0.0¢ 0%
2009 0.0¢ 0%
2010 0.0¢ 0%
2011 0.0¢ 0%
2012 0.0¢ 0%
2013 0.0¢ 0%
2014 0.0¢ 0%
2015 0.0¢ 0%
2016 0.0¢ 0%
2017 0.0¢ 0%
2018 Login required


Ex-Div Date Pay Date Year Type Frequency Status Amount

Galapagos optimized dividend - 12 month history

Optimized dividend graph demo

Galapagos share price - 12 month history

You're currently viewing outdated and/or artificial data.

Try the real thing now:

Activate Free Trial